Navigation Links
Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/11/2008

wth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect", "anticipate", "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the optimal dose level for future clinical trials; completion of the Phase 1 trial; the launching of a comprehensive Phase 2 program in patients with CIN; the number of cohorts and patients and the expected dosing amounts in the Phase 1 trial; and the collection and use of immunological data to indicate potential activity of new HspE7.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our need for capital; the outcomes of our clinical trials; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations o
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
5. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
8. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
9. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
10. Northwestern Memorial Transplant Program Initiates New Study
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... , Oct. 16, 2014 The ... guidance on the application of single-use, or ... pharmaceutical and biopharmaceutical products with the publication ... Application of Single-Use Systems in Pharmaceutical ... described as single-use systems (SUS) or single-use ...
(Date:10/16/2014)... , Oct. 16, 2014 Curtis & ... under 3 weeks away from hosting their co-located ... Oral Drug Formulation Innovations Summit taking place ... San Diego, CA. November,s events ... organizations in streamlining the bioequivalence testing process, as well ...
(Date:10/16/2014)... PHILADELPHIA , Oct. 16, 2014 Ninety ... (ALL) who had relapsed multiple times or failed to ... an investigational personalized cellular therapy, CTL019, developed at the ... The results published today in The ... new data, which builds on preliminary findings presented at ...
Breaking Medicine Technology:PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
... Health Corp. (Nasdaq: WBMD ) today announced the ... amount of 2.50% Convertible Notes due 2018 (including $50 million ... full of the initial purchaser,s over-allotment option).  The notes were ... under the Securities Act of 1933.   The ...
... NEW YORK, Jan. 11, 2011 Reportlinker.com ... is available in its catalogue: ... Price cuts set to negatively impact both ... http://www.reportlinker.com/p0360216/Spain-Pharmaceutical-Market-Overview – Price-cuts-set-to-negatively-impact-both-branded-and-generics-companies.html ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies 2
(Date:10/19/2014)... 19, 2014 One major trend in ... therapy despite the high-cost structure leading to the implementation ... , Analysts forecast the Global Proton Therapy market ... over the period 2013-2018. According to the report, one ... technological advances in medical diagnostics and therapeutics. The advances ...
(Date:10/18/2014)... 19, 2014 The famous review site ... After evaluating many web host suppliers carefully, today it ... PHP Hosting suppliers in the first half of 2014. ... international market. Its internet hosting package helps business companies ... the cost. As a top rated hosting provider, it ...
(Date:10/18/2014)... October 19, 2014 The ... that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), JustHost and ... in 2014. , “There are thousands ... but good suppliers are not too many. ... FatCow are the most outstanding suppliers when ...
(Date:10/18/2014)... 19, 2014 Operators in the ... provide professional carpet cleaning services, such as steam ... professionally cleaned every one to two years. According ... industry services plummeted during the peak of the ... including professional carpet cleaning.” The upward trend in ...
(Date:10/18/2014)... October 18, 2014 Market ... sulfate Industry, 2009-2019 is a professional and ... Chinese Chondroitin sulfate industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Chondroitin sulfate listing their ...
Breaking Medicine News(10 mins):Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 2Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 3Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 4Health News:Top10BestSEOHosting.com: HostMonster, GreenGeeks And FatCow Are The Best PHP Hosting Suppliers In The First Half Of 2014 2Health News:Top10BestSEOHosting.com: Best Reseller Hosting Companies Announced 2Health News:Carpet Cleaning Services in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Carpet Cleaning Services in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 2Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 3Health News:Chondroitin Sulfate Industry Global & Chinese Forecast to 2019 Now Available at RnRMarketResearch.com 4
... Loss of Legal Remedies, SANTA MONICA, Calif., ... more than 1,000 patients whose health coverage,was retroactively ... it,acknowledges that patients can make claims for repayment ... or loss of a home.,In past proposals patients ...
... nutritional analysis for more than 25,000 foods and 10,000 ... ... - A simple, one-stop resource for counting carbohydrates -, WESTPORT, ... the launch of the dLife Recipe Finder,and Food Look-Up, the world,s ...
... data on worldwide cancer incidence, researchers at the Moores ... and the Department of Family and Preventive Medicine have ... sunlight, specifically ultraviolet B (UVB), and breast cancer. ... the body. This form of vitamin D also is ...
... Department of Justice,s enforcement action in Sierra acquisition ... 15 The American Medical,Association, Nevada State Medical ... have filed joint comments seeking to reject,the final ... in the,acquisition of Sierra Health Services by United ...
... Business,Council (USCBC) today encouraged American companies to continue ... response to the devastating earthquake,that hit Sichuan Province ... already pledged several million dollars in,cash and in-kind ... and many,have established matching funds for their employees., ...
... from Larry Minnix, President & CEO, American Association of ... points out yet again that we need comprehensive,reform of ... country. If,we want to assure quality and safety for ... the bottom up., "There is no evidence, however, ...
Cached Medicine News:Health News:Consumer Watchdog Raises Concern That Health Policy Cancellation Rules Have Been Derailed in Deal With Kaiser 2Health News:Consumer Watchdog Raises Concern That Health Policy Cancellation Rules Have Been Derailed in Deal With Kaiser 3Health News:dLife Launches the World's Largest and Most Comprehensive Online Food and Diabetic Recipe Search Tool 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Physicians Charge Health Insurer Merger Not In The Public Interest 2Health News:US Companies Aid Chinese Earthquake Victims 2Health News:US Companies Aid Chinese Earthquake Victims 3Health News:US Companies Aid Chinese Earthquake Victims 4Health News:US Companies Aid Chinese Earthquake Victims 5Health News:US Companies Aid Chinese Earthquake Victims 6Health News:US Companies Aid Chinese Earthquake Victims 7
... physicians looking for a traditional ... communications with electronic storage features, ... best of both worlds. It ... features of the Atria 3000 ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: